Patient Preferences for Nonvitamin K Antagonist Oral Anticoagulants in Stroke Prevention: A Multicountry Discrete Choice Experiment
Purpose. The patient’s perspective is becoming increasingly important in clinical and policy decisions. This study examined atrial fibrillation (AF) patient preferences for different characteristics of nonvitamin K antagonist oral anticoagulants (NOACs). Methods. A discrete choice experiment (DCE) a...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Cardiology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2019/5719624 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561203058049024 |
|---|---|
| author | Thomas Wilke Anna-Katharina Meinecke Bernhard Schaefer Sandra Buchwald Daniel Eriksson Sabrina Müller |
| author_facet | Thomas Wilke Anna-Katharina Meinecke Bernhard Schaefer Sandra Buchwald Daniel Eriksson Sabrina Müller |
| author_sort | Thomas Wilke |
| collection | DOAJ |
| description | Purpose. The patient’s perspective is becoming increasingly important in clinical and policy decisions. This study examined atrial fibrillation (AF) patient preferences for different characteristics of nonvitamin K antagonist oral anticoagulants (NOACs). Methods. A discrete choice experiment (DCE) addressing AF patients treated with NOACs in France, Germany, and the United Kingdom was conducted. The DCE included the following attributes: frequency of administration (once/twice daily), size of tablet/capsule (6–9 mm/20 mm), meal-related intake (intake with food required/independent), and distance to treating physician (1 km/10 km). Preferences were analyzed based on a conditional logit regression model. Results. In total, 758 patients (males: 57.3%; mean age: 71.4 years) with an average disease duration of 5.5 years were included (apixaban/dabigatran/edoxaban/rivaroxaban: 34.0%/14.5%/6.6%/44.9%, respectively). Patients preferred NOAC treatment options characterized by once-daily dosing regimens (42.8%; p<0.001), shorter distance to treating physicians (25.0%; p<0.001), a small-sized tablet (21.5%; p<0.001), and intake independent of food (10.6%; p<0.001). Conclusions. Patients primarily prefer a once-daily NOAC regimen. Individual preferences should be considered for the treatment of AF patients as this may result in improved treatment adherence and consequently better effectiveness and safety in routine clinical practice. |
| format | Article |
| id | doaj-art-1a9d6e10baf44a3ab1aa30aa891b2436 |
| institution | Kabale University |
| issn | 2090-8016 2090-0597 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiology Research and Practice |
| spelling | doaj-art-1a9d6e10baf44a3ab1aa30aa891b24362025-02-03T01:25:37ZengWileyCardiology Research and Practice2090-80162090-05972019-01-01201910.1155/2019/57196245719624Patient Preferences for Nonvitamin K Antagonist Oral Anticoagulants in Stroke Prevention: A Multicountry Discrete Choice ExperimentThomas Wilke0Anna-Katharina Meinecke1Bernhard Schaefer2Sandra Buchwald3Daniel Eriksson4Sabrina Müller5Ingress-Health HWM GmbH, 23966 Wismar, GermanyBayer AG, 13342 Berlin, GermanyBayer AG, 13342 Berlin, GermanyBayer AG, 13342 Berlin, GermanyBayer AG, 13342 Berlin, GermanyIngress-Health HWM GmbH, 23966 Wismar, GermanyPurpose. The patient’s perspective is becoming increasingly important in clinical and policy decisions. This study examined atrial fibrillation (AF) patient preferences for different characteristics of nonvitamin K antagonist oral anticoagulants (NOACs). Methods. A discrete choice experiment (DCE) addressing AF patients treated with NOACs in France, Germany, and the United Kingdom was conducted. The DCE included the following attributes: frequency of administration (once/twice daily), size of tablet/capsule (6–9 mm/20 mm), meal-related intake (intake with food required/independent), and distance to treating physician (1 km/10 km). Preferences were analyzed based on a conditional logit regression model. Results. In total, 758 patients (males: 57.3%; mean age: 71.4 years) with an average disease duration of 5.5 years were included (apixaban/dabigatran/edoxaban/rivaroxaban: 34.0%/14.5%/6.6%/44.9%, respectively). Patients preferred NOAC treatment options characterized by once-daily dosing regimens (42.8%; p<0.001), shorter distance to treating physicians (25.0%; p<0.001), a small-sized tablet (21.5%; p<0.001), and intake independent of food (10.6%; p<0.001). Conclusions. Patients primarily prefer a once-daily NOAC regimen. Individual preferences should be considered for the treatment of AF patients as this may result in improved treatment adherence and consequently better effectiveness and safety in routine clinical practice.http://dx.doi.org/10.1155/2019/5719624 |
| spellingShingle | Thomas Wilke Anna-Katharina Meinecke Bernhard Schaefer Sandra Buchwald Daniel Eriksson Sabrina Müller Patient Preferences for Nonvitamin K Antagonist Oral Anticoagulants in Stroke Prevention: A Multicountry Discrete Choice Experiment Cardiology Research and Practice |
| title | Patient Preferences for Nonvitamin K Antagonist Oral Anticoagulants in Stroke Prevention: A Multicountry Discrete Choice Experiment |
| title_full | Patient Preferences for Nonvitamin K Antagonist Oral Anticoagulants in Stroke Prevention: A Multicountry Discrete Choice Experiment |
| title_fullStr | Patient Preferences for Nonvitamin K Antagonist Oral Anticoagulants in Stroke Prevention: A Multicountry Discrete Choice Experiment |
| title_full_unstemmed | Patient Preferences for Nonvitamin K Antagonist Oral Anticoagulants in Stroke Prevention: A Multicountry Discrete Choice Experiment |
| title_short | Patient Preferences for Nonvitamin K Antagonist Oral Anticoagulants in Stroke Prevention: A Multicountry Discrete Choice Experiment |
| title_sort | patient preferences for nonvitamin k antagonist oral anticoagulants in stroke prevention a multicountry discrete choice experiment |
| url | http://dx.doi.org/10.1155/2019/5719624 |
| work_keys_str_mv | AT thomaswilke patientpreferencesfornonvitaminkantagonistoralanticoagulantsinstrokepreventionamulticountrydiscretechoiceexperiment AT annakatharinameinecke patientpreferencesfornonvitaminkantagonistoralanticoagulantsinstrokepreventionamulticountrydiscretechoiceexperiment AT bernhardschaefer patientpreferencesfornonvitaminkantagonistoralanticoagulantsinstrokepreventionamulticountrydiscretechoiceexperiment AT sandrabuchwald patientpreferencesfornonvitaminkantagonistoralanticoagulantsinstrokepreventionamulticountrydiscretechoiceexperiment AT danieleriksson patientpreferencesfornonvitaminkantagonistoralanticoagulantsinstrokepreventionamulticountrydiscretechoiceexperiment AT sabrinamuller patientpreferencesfornonvitaminkantagonistoralanticoagulantsinstrokepreventionamulticountrydiscretechoiceexperiment |